02:32 PM EDT, 10/24/2025 (MT Newswires) -- Sagimet Biosciences ( SGMT ) shares rose more than 25% in recent Friday trading after the company said a phase 3 trial of denifanstat in patients with moderate to severe acne vulgaris met all primary and secondary endpoints and was generally well tolerated.

The study, conducted by its license partner in China, Ascletis Bioscience, showed treatment success rates with denifanstat were more than double those of placebo.

Primary endpoints included the percentage of treatment success, the percentage change in total lesion count, and the percentage change in inflammatory lesion count.

Earlier in the month, Ascletis said it completed a pre-New Drug Application consultation with China's National Medical Products Administration and plans to submit the application soon.

Price: 9.20, Change: +1.87, Percent Change: +25.51